John Wysolmerski

John Wysolmerski

Auto-generated profile, based on publicly available information

John Wysolmerski

Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine , New Haven, CT

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
CRChristian Felipe. Ruiz
Christian Felipe. Ruiz
XGXiangyu Ge
Xiangyu Ge
RMRylee McDonnell
Rylee McDonnell
SASherry S. Agabiti
Sherry S. Agabiti
DMDaniel C. McQuaid
Daniel C. McQuaid
MMMandar Deepak. Muzumdar
Mandar Deepak. Muzumdar
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive cancer development remains unresolved. Leveraging an oncogenic Kras-driven mouse model that closely mimics human PDAC progression, we screened a dozen isocaloric HFDs differing solely in fat source and representing the diversity of human fat consumption. Unexpectedly, diets rich in oleic acid – a monounsaturated fatty acid (MUFA) typically associated with good health – markedly enhanced tumorigenesis. Conversely, diets high in polyunsaturated fatty acids (PUFAs) suppressed tumor progression. Relative dietary fatty acid saturation levels (PUFA/MUFA) governed pancreatic membrane phospholipid composition, lipid peroxidation, and ferroptosis sensitivity in mice, concordant with circulating PUFA/MUFA levels being linked to altered PDAC risk in humans. These findings directly implicate dietary unsaturated fatty acids in controlling ferroptosis susceptibility and tumorigenesis, supporting potential “precision nutrition” strategies for PDAC prevention.

26 June 2023 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
INIsabella Niu
Isabella Niu
EHEdward Hsiao
Edward Hsiao
RWRosanna Wustrack
Rosanna Wustrack
JWJohn J. Wysolmerski
John J. Wysolmerski
PDPamela Dann
Pamela Dann
UMUmesh Masharani
Umesh Masharani
The treatment of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia of malignancy includes treating the malignancy, intravenous fluids, and anti-resorptive therapies such as zoledronic acid or denosumab. PTHrP-mediated hypercalcemia has been reported in benign conditions such as systemic lupus erythematous (SLE) and sarcoidosis and appears to be responsive to glucocorticoids. We report a case of PTHrP-induced hypercalcemia due to a malignancy—low grade fibromyxoid sarcoma—that responded to glucocorticoid treatment. This is the first report of glucocorticoids controlling PTHrP-mediated hypercalcemia of malignancy. Immunohistochemistry of the surgical pathology localized PTHrP staining to the vascular endothelial cells within the tumor. Further studies are needed to elucidate the mechanism of glucocorticoid action in the treatment of PTHrP-mediated hypercalcemia of malignancy.


1 January 2003
Verified
Book Chapter
Closed access
JHJoshua N. Van Houten
Joshua N. Van Houten
JWJohn J. Wysolmerski
John J. Wysolmerski

18 June 2026 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
MMM Matthews
M Matthews
RCR Cooper
R Cooper
SDS L Dallas
S L Dallas
SKSundeep Khosla
Sundeep Khosla
KLK Lengyel
K Lengyel
JWJ J Wysolmerski
J J Wysolmerski
In 2024, the National Academies of Sciences, Engineering, and Medicine (NASEM) published a report entitled Advancing Research on Chronic Conditions in Women. A major purpose of this report was to summarize the current state of research into a series of 21 chronic conditions that affect women differently or that are more common in women. The American Society for Bone and Mineral Research (ASBMR) established a working group to evaluate the NASEM report’s implications for women’s MSK health. This perspective summarizes key research gaps identified in the NASEM report, including the lack of sex-specific data, underrepresentation of women in clinical studies, and minimal integration of MSK health with other chronic conditions. The NASEM report underscores the need for more comprehensive study designs that consider hormonal, genetic, and social determinants of health across the lifespan. In addition to osteoporosis, in this perspective, the ASBMR working group highlights emerging but poorly understood evidence of detrimental effects on musculoskeletal biology in non-MSK, chronic diseases that were identified in the NASEM report to disproportionately affect women. To advance the field, we advocate for better diagnostics, increased investment, and stronger representation of women in research studies. Addressing these gaps is critical for improving prevention, care, and outcomes for chronic conditions that uniquely or disproportionately affect women.

1 October 2026
Verified
Other
Open access
CRChristian Felipe Ruiz
Christian Felipe Ruiz
XGXiangyu Ge
Xiangyu Ge
RMRylee McDonnell
Rylee McDonnell
SASherry S. Agabiti
Sherry S. Agabiti
DMDaniel C. McQuaid
Daniel C. McQuaid
MMMandar Deepak Muzumdar
Mandar Deepak Muzumdar
Supplementary Table S4 shows RNA-seq analyses of high-fat diet-fed mice.